Literature DB >> 1713161

Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts.

C A Conover1, D R Powell.   

Abstract

Insulin-like growth factor-I (IGF-I) initiates its diverse biological effects by binding to type I IGF receptors on cells. In addition, IGF-I associates with distinct proteins that can modulate its actions. One of these IGF-binding proteins, IGFBP-3, is the major circulating form in adults and is produced by many cells in culture. We investigated the effect of purified bovine IGFBP-3 on IGF-I binding and IGF-I stimulation of amino acid uptake and DNA synthesis in cultured bovine fibroblasts, a cell culture system highly suitable for these types of studies. Incubation of cells with IGF-I resulted in time- and dose-dependent decreases in [125I]IGF-I binding and IGF-I stimulated [3H]aminoisobutyric acid uptake and [3H]thymidine incorporation. Preincubation with 4 nM IGF-I resulted in a 50-60% decrease in IGF-I receptor binding, accompanied by marked decreases in IGF-I-stimulated [3H]aminoisobutyric acid uptake (50-60%) and [3H]thymidine incorporation (80-90%). Preincubation with the IGF-I analog [QAYL]IGF-I (4 nM) or with 100 nM insulin, growth factors that bind and activate type I IGF receptor signalling but have little or no affinity for IGFBP-3, had effects comparable to IGF-I, decreasing both IGF-I binding and action 50-95%. The addition of IGFBP-3 during the preincubation period with IGF-I blocked the decrease in receptor availability and prevented the cells from becoming desensitized. IGFBP-3 did not prevent the [QAYL]IGF-I- or insulin-induced receptor loss and cellular resistance to IGF-I. These data indicate that IGFBP-3 can prevent IGF-I-induced receptor down-regulation, a process that renders cells refractory to further stimulation by IGF-I. Thus, cell-derived IGFBP-3 may function in a buffering capacity to restrict IGF-I and target cell interaction, thereby modulating the biological response to changes in local IGF-I levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713161     DOI: 10.1210/endo-129-2-710

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

Review 1.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 2.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

3.  Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia.

Authors:  Si Won Lee; Soo Yoon Lee; Sa Ra Lee; Woong Ju; Seung Cheol Kim
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

Review 4.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis.

Authors:  Astrid C Baege; Gary L Disbrow; Richard Schlegel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Follicular fluid insulin-like growth factor-I and insulin-like growth factor-binding protein-1 and -3 vary as a function of ovarian reserve and ovarian stimulation.

Authors:  L Stadtmauer; A Vidali; S R Lindheim; M V Sauer
Journal:  J Assist Reprod Genet       Date:  1998-11       Impact factor: 3.412

Review 7.  IGFs and cellular aging.

Authors:  C A Conover
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 8.  Insulin-like growth factor (IGF) system in the bovine mammary gland and milk.

Authors:  C R Baumrucker; N E Erondu
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 9.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

10.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.